Recent ALDX News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 11:01:12 AM
- Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease • Business Wire • 10/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:10:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:22 PM
- Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 01:02:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 10:07:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 09:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:48 AM
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap • Business Wire • 08/08/2024 11:00:00 AM
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap • Business Wire • 08/07/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/01/2024 09:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:11:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:03:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:40 AM
- Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 11:01:34 AM
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease • Business Wire • 06/13/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Investor Roundtable Q&A • Business Wire • 06/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:09 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM